Quantcast
Last updated on April 20, 2014 at 19:30 EDT

Latest Sinovac Biotech Ltd. Stories

2010-05-24 07:00:00

BEIJING, May 24 /PRNewswire-Asia/ -- Sinovac Biotech Ltd. (Nasdaq: SVA), a leading China-based vaccine manufacturer, announced today that Mr. Weidong Yin, Chairman, President & CEO, will present at the 2010 UBS Global Specialty Pharmaceuticals Conference, which is being held June 2-3, 2010 in London, England. Sinovac's presentation is scheduled for Wednesday, June 2, 2010 at 10 a.m. BST/5 a.m. Eastern Time. A live webcast of the presentation will be available online on the...

2010-05-13 16:00:00

BEIJING, May 13 /PRNewswire-Asia/ -- Sinovac Biotech Ltd. (Nasdaq: SVA), a leading China-based vaccine manufacturer, announced today its unaudited financial results for the three-month period ended March 31, 2010. First Quarter 2010 Financial Highlights (comparisons to First Quarter 2009) -- Sales for the first quarter decreased 32% to $4.4 million -- Operating loss for the first quarter was $865,000, compared to operating income of $646,000 -- Net loss...

2010-05-06 07:00:00

BEIJING, May 6 /PRNewswire-Asia/ -- Sinovac Biotech Ltd. (Nasdaq: SVA), a leading provider of vaccines in China, today announced that it will release its financial results for the first quarter ended March 31, 2010 after the close of the market on Thursday, May 13, 2010. The Company will host a conference call on Thursday, May 13, 2010 at 8:00 p.m. ET to review the Company's financial results and provide an update on recent corporate developments. To access the conference call,...

2010-05-05 07:00:00

BEIJING, May 5 /PRNewswire-Asia/ -- Sinovac Biotech Ltd. (Nasdaq: SVA), a leading China-based vaccine manufacturer, announced today that its 30%-owned joint venture, Sinovac Dalian, has submitted an application to China's State Food and Drug Administration (SFDA) to commence human clinical trials for its mumps vaccine. The proprietary mumps vaccine developed by Sinovac Dalian represents not only the first live attenuated vaccine for which Sinovac has filed a clinical trial application,...

2010-04-16 07:00:00

BEIJING, April 16 /PRNewswire-Asia/ -- Sinovac Biotech Ltd. (Nasdaq: SVA), a leading China-based vaccine manufacturer, announced today it filed its annual report on Form 20-F for the fiscal year ended December 31, 2009 with the Securities and Exchange Commission on April 16, 2010. The annual report on Form 20-F can be accessed on Sinovac's website at http://www.sinovac.com/Investors/SECFilings/ . Sinovac will provide a hard copy of the annual report containing its audited consolidated...

2010-04-06 06:46:00

BEIJING, April 6 /PRNewswire-Asia/ -- Sinovac Biotech Ltd. (Nasdaq: SVA), a leading China-based vaccine manufacturer, announced today its unaudited financial results for the three-month and preliminary twelve-month periods ended December 31, 2009. Financial Highlights -- Sales for the fourth quarter increased 194% to $36.4 million -- Sales for the twelve-month period grew 81% to $84.2 million -- Operating income for the fourth quarter rose 449% to $17.1 million --...

2010-03-23 07:00:00

BEIJING, March 23 /PRNewswire-Asia/ -- Sinovac Biotech Ltd. (Nasdaq: SVA), a leading China-based vaccine manufacturer, announced today that Mr. Weidong Yin, Chairman, President and CEO of Sinovac, is scheduled to partake in Track One: Pharmaceuticals and Biotech at the Inaugural China Healthcare Investment Conference on March 30, 2010. Sinovac is one of five publicly traded life sciences companies that will make a 20-minute company presentation starting at 9:35 a.m. China Standard Time...

2010-02-15 07:00:00

BEIJING, Feb. 15 /PRNewswire-Asia/ -- Sinovac Biotech Ltd. (Nasdaq: SVA), a leading China-based vaccine manufacturer, today announced the completion by its subsidiary, Sinovac Beijing, of the acquisition of buildings and land use rights. The total consideration for the purchase is approximately RMB120 million ($17.6 million), which will be financed from working capital. The initial payment of RMB56.5 million ($8.3 million) will be paid before February 20, 2010 and the balance of the...

2010-02-02 15:05:00

BEIJING, Feb. 2 /PRNewswire-Asia/ -- Sinovac Biotech Ltd. (Nasdaq: SVA) ("Sinovac" or the "Company"), a leading China-based vaccine manufacturer, announced today that its previously announced public common share offering was closed on February 2, 2010. Sinovac received net proceeds of approximately $62.0 million, after deducting underwriting discounts and commissions and estimated offering expenses payable by the Company, which included net proceeds from the sale of 1,500,000 common...

2010-02-01 07:55:00

BEIJING, Feb. 1 /PRNewswire-Asia/ -- Sinovac Biotech Ltd. (Nasdaq: SVA) ("Sinovac" or the "Company"), a leading China-based vaccine manufacturer, announced today that the underwriters of its previously announced public common share offering have exercised in full their option to purchase an additional 1,500,000 common shares to cover over-allotments in the offering. As a result, Sinovac will issue and sell a total of 11,500,000 common shares at $5.75 per common share in this offering,...